Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target at HC Wainwright
HC Wainwright set a $22.00 price target on Iovance Biotherapeutics (NASDAQ:IOVA) in a research note released on Thursday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Other analysts have also issued reports about the stock. B. Riley boosted their price target on shares of Iovance Biotherapeutics from $17.50 to $18.00 and gave the stock a buy rating in a research note on Wednesday, November 1st. Oppenheimer set a $13.00 price target on shares of Iovance Biotherapeutics and gave the stock a buy rating in a research note on Tuesday, October 31st. Jefferies Group reiterated a buy rating on shares of Iovance Biotherapeutics in a research note on Sunday, October 29th. FBR & Co reiterated a buy rating and set a $17.50 price target on shares of Iovance Biotherapeutics in a research note on Wednesday, October 25th. Finally, Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a hold rating to a buy rating and set a $8.25 price target on the stock in a research note on Tuesday, October 17th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Iovance Biotherapeutics presently has a consensus rating of Buy and a consensus price target of $18.75.
Shares of Iovance Biotherapeutics (NASDAQ:IOVA) opened at $16.80 on Thursday. The stock has a market cap of $1,220.00, a PE ratio of -12.82 and a beta of 6.20. Iovance Biotherapeutics has a one year low of $4.45 and a one year high of $18.15.
ILLEGAL ACTIVITY WARNING: “Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target at HC Wainwright” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/iovance-biotherapeutics-iova-given-a-22-00-price-target-at-hc-wainwright/1860128.html.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.